Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems ORLANDO, Fla. (May 9, 2024) – LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives. Exhibit ...

FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...

Revenue Performance - Total revenue for Q4 2023 was $12.1 million, an increase of 18% compared to $10.2 million in Q4 2022[3] - Full-year revenue for 2023 reached $42.2 million, up 19% from $35.4 million in 2022[8] - Total revenue for Q4 2023 was $12,105,000, representing a 18.3% increase from $10,232,000 in Q4 2022[29] - Product revenue increased to $9,452,000 in Q4 2023, up 21.6% from $7,771,000 in Q4 2022[29] Expenses and Losses - Net loss for Q4 2023 was $3.9 million, or ($0.35) per share, compared to a net loss of $2.5 million, or ($0.24) per share, in Q4 2022[6] - Selling, general and administrative expenses for Q4 2023 were $6.4 million, a decrease of 12% from $7.2 million in Q4 2022[4] - Research and development expenses decreased to $1.5 million in Q4 2023, down 9% from $1.6 million in Q4 2022[5] - Adjusted EBITDA for Q4 2023 was $(1,221,000), compared to $(65,000) in Q4 2022[27] - Net loss for the twelve months ended December 31, 2023, was $(14,383,000), an improvement from $(19,914,000) in 2022[29] - Operating loss for the twelve months ended December 31, 2023, was $(12,229,000), an improvement from $(20,177,000) in 2022[29] - Research and development expenses for the twelve months ended December 31, 2023, were $6,139,000, down from $11,814,000 in 2022[29] - Net loss per common share for the twelve months ended December 31, 2023, was $(1.31), an improvement from $(1.96) in 2022[29] Cash and Assets - Cash and cash equivalents as of December 31, 2023, were $24.6 million, up from $14.7 million at the end of 2022[15] - Cash and cash equivalents increased to $20,621,000 as of December 31, 2023, up from $14,674,000 in 2022[31] - Total assets grew to $69,585,000 in 2023, compared to $55,844,000 in 2022, reflecting a 24.6% increase[31] - Total liabilities increased to $22,409,000 in 2023, compared to $13,860,000 in 2022[31] Operational Highlights - 44 ALLY Adaptive Cataract Treatment Systems were placed in 2023, exceeding the target of 30, with a backlog of 9 systems as of December 31, 2023[1] - Approximately 73% of revenue in Q4 2023 was attributable to recurring sources, compared to 86% in Q4 2022[9] - Procedure volume for 2023 totaled 137,012, a slight increase from 132,113 in 2022, with a 15% increase when excluding South Korea[9][10] Future Outlook - The company expects to secure additional regulatory approvals for the ALLY System in international markets in 2024[2]

LENSAR, Inc. (NASDAQ:LNSR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning, and thank you for your participation. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Cameron Radinovic of Burns McClellan, Mr. Radinovic, please go ahead. Cameron Radinovic Tha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 32-0125724 (State or other jurisdiction ...

LENSAR, Inc. (NASDAQ:LNSR) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Cameron Radinovic – Burns McClellan Nick Curtis – Chief Executive Officer Tom Staab – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Operator Good morning and thank you for your participation. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. As a reminder, this conference call will be recorded. I would now like to ...

(Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 32-0125724 (State or other jurisdiction of in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) Delaware 32-0125724 (State or other jurisdiction of i ...

Financial Data and Key Metrics - Revenue for Q1 2023 was $8.3 million, down from $9.3 million in Q1 2022, primarily due to a $1.5 million decrease in revenue from South Korea [22] - Gross margin for Q1 2023 was 52%, up from 50% in Q1 2022, driven by higher-margin procedures in the US and Europe [25] - Net loss for Q1 2023 was $4.3 million, or $0.40 per share, compared to a net loss of $6.7 million, or $0.67 per share, in Q1 2022 [29] - Cash and cash equivalents stood at $8 million as of March 31, 2023, down from $14.7 million at the end of 2022 [29] Business Line Performance - The company installed five ALLY systems in Q1 2023 and four more since April 1, bringing the total install base to 19, with an additional 13 systems in backlog [8] - Procedure volumes in the US increased by 13% compared to Q1 2022, driven by the growing adoption of ALLY systems [23] - In South Korea, procedure volumes decreased by approximately 9,900 procedures, contributing to a 19% overall decline in procedure volumes compared to Q1 2022 [18][24] Market Performance - The US market accounted for 15% of all femtosecond laser-assisted cataract surgical procedures in Q1 2023, up 100 basis points from Q2 2022 [11] - Procedure volumes in Europe increased by 5% compared to Q1 2022 [23] - South Korea's market challenges, particularly with third-party payors, led to a significant decline in procedure volumes and revenue, with no clear resolution timeframe [18][19] Strategic Direction and Industry Competition - The company is focused on expanding the reach of its ALLY system, which has been well-received by the ophthalmic community, with early adopters reporting significant productivity improvements [10][12] - LENSAR has secured its first multi-system agreements and is working on additional contracts, indicating strong demand for ALLY [16][17] - The company is leveraging its advanced technology and marketing efforts to maintain a competitive edge, including active participation in major ophthalmic congresses [15] Management Commentary on Operating Environment and Future Outlook - Management highlighted the positive reception of ALLY, with early adopters reporting time savings of 1.5 to 2 hours per surgical day, leading to increased productivity and ROI [37] - Supply chain issues are easing, with greater availability of raw materials expected to improve ALLY manufacturing efficiency in the remainder of 2023 [26] - The company completed a $20 million private placement, extending its cash runway and enabling strategic investments in inventory, sales, and marketing to capitalize on ALLY's early success [20][30] Other Important Information - The company expects R&D expenditures for 2023 to approximate $7 million, consistent with Q1 2023 levels [28] - LENSAR's remote diagnostic capabilities and service infrastructure are key differentiators, ensuring high system uptime and customer satisfaction [55] Q&A Session Summary Question: Productivity improvements from ALLY adoption - Early adopters of ALLY have reported significant time savings, enabling them to perform 3-4 additional cases per day or reduce overhead costs [37] - Transitioning from previous-generation systems to ALLY has resulted in a 20% increase in procedure volumes among early adopters [38] Question: Customer preferences for ALLY acquisition (leases vs. outright sales) - Customers are increasingly opting for operating leases or outright purchases, depending on their accounting practices and access to tax benefits [40] - The company has seen a higher percentage of systems being purchased outright or through operating leases, with per-procedure fees remaining a consistent component [40] Question: Revenue growth expectations for 2023 - The company anticipates at least 20% revenue growth in 2023, despite challenges in the South Korean market, driven by strong demand for ALLY in the US [48] - Gross margins are expected to remain around 50-52% for 2023, with potential for improvement as supply chain issues abate [50] Question: Cash runway and private placement terms - The $20 million private placement significantly extends the company's cash runway, enabling investments in inventory and sales/marketing to support ALLY's launch [30][52] - Management considered alternative financing options but opted for the private placement due to favorable terms and the need to address immediate liquidity concerns [61][62] Question: Margin improvements and future expectations - Gross margin improvements in Q1 2023 were attributed to higher-margin procedures in the US and Europe, offsetting declines in South Korea [25] - Margins are expected to remain stable in the low 50s for 2023, with potential for further improvement as supply chain challenges ease [50]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39473 LENSAR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...